SCHEMBL17513282

SCHEMBL17513282

O=C1CCNc2c(Cl)cc(Cl)cc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 1.00
KMT2A Q03164 4/20 1.00
L3MBTL1 Q9Y468 1/20 1.00
MAPT P10636 4/20 0.59
CES1 P23141 3/20 0.46
DNMT1 P26358 1/20 0.46
PARP10 Q53GL7 2/20 0.42
F7 P08709 1/20 0.42
PARP1 P09874 1/20 0.42
F3 P13726 1/20 0.42
ALDH1A1 P00352 5/20 0.39
HTT P42858 3/20 0.39
GAA P10253 3/20 0.39
HSD17B10 Q99714 3/20 0.39
HPGD P15428 2/20 0.39
TP53 P04637 2/20 0.39
ALOX15 P16050 2/20 0.39
ALOX12 P18054 2/20 0.39
MPI P34949 2/20 0.39
LMNA P02545 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2278697 0.82 MEN1 (0.70) MEN1KMT2AL3MBTL1MAPTCES1
SCHEMBL9037964 0.82 KMT2A (0.70) MEN1KMT2AL3MBTL1MAPTCES1
SCHEMBL8188585 0.82 MEN1 (0.70) MEN1KMT2AL3MBTL1MAPTPARP10
SCHEMBL23846921 0.82 MEN1 (0.70) MEN1KMT2AL3MBTL1MAPTPARP10
SCHEMBL9035160 0.77 KMT2A (0.62) MEN1KMT2AL3MBTL1MAPTPARP10
SCHEMBL7666502 0.76 MEN1 (0.60) MEN1KMT2AL3MBTL1MAPTPARP10
SCHEMBL9803790 0.74 MAPT (1.00) MEN1KMT2AL3MBTL1MAPTCES1
SCHEMBL11011233 0.73 MEN1 (0.56) MEN1KMT2AL3MBTL1MAPT
SCHEMBL4869956 0.72 MEN1 (0.56) MEN1KMT2AL3MBTL1MAPTCES1
SCHEMBL9514990 0.72 MEN1 (0.56) MEN1KMT2AL3MBTL1MAPTCES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016029146-A1 SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE UNIVERSITY OF WASHINGTON (US) 2016-02-25 WO claimed
US-10913736-B2 Specific inhibitors of methionyl-tRNA synthetase UNIVERSITY OF WASHINGTON (US) 2021-02-09 US disclosed
US-10913736-B2 Specific inhibitors of methionyl-tRNA synthetase UNIVERSITY OF WASHINGTON (US) 2021-02-09 US disclosed
US-20170275279-A1 SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE UNIVERSITY OF WASHINGTON 2017-09-28 US disclosed
US-20170275279-A1 SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE UNIVERSITY OF WASHINGTON 2017-09-28 US disclosed
US-20170275279-A1 SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE UNIVERSITY OF WASHINGTON 2017-09-28 US disclosed
WO-2016029146-A1 SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE UNIVERSITY OF WASHINGTON (US) 2016-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170275279-A1 SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE AARS1, MTR, GARS1 MEN1 2418/4885KMT2A 1195/4885L3MBTL1 232/4885
US-10913736-B2 Specific inhibitors of methionyl-tRNA synthetase AARS1, MTR, GARS1 MEN1 2418/4885KMT2A 1195/4885L3MBTL1 232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.